KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) EBIT: 2009-2024

Historic EBIT for Neogenomics (NEO) over the last 16 years, with Dec 2024 value amounting to -$92.1 million.

  • Neogenomics' EBIT fell 27.44% to -$27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$120.9 million, marking a year-over-year decrease of 30.98%. This contributed to the annual value of -$92.1 million for FY2024, which is 14.51% up from last year.
  • According to the latest figures from FY2024, Neogenomics' EBIT is -$92.1 million, which was up 14.51% from -$107.7 million recorded in FY2023.
  • Over the past 5 years, Neogenomics' EBIT peaked at -$14.0 million during FY2020, and registered a low of -$157.6 million during FY2022.
  • Moreover, its 3-year median value for EBIT was -$107.7 million (2023), whereas its average is -$119.2 million.
  • Per our database at Business Quant, Neogenomics' EBIT tumbled by 748.73% in 2021 and then skyrocketed by 31.65% in 2023.
  • Yearly analysis of 5 years shows Neogenomics' EBIT stood at -$14.0 million in 2020, then crashed by 748.73% to -$118.8 million in 2021, then slumped by 32.73% to -$157.6 million in 2022, then soared by 31.65% to -$107.7 million in 2023, then increased by 14.51% to -$92.1 million in 2024.